Abstract

Community acquired pneumonia (CAP) is a common cause of hospital admission. The first 24–48 hours are crucial in the correct diagnosis and management of CAP. In this article we highlight the pitfalls in diagnosis and the important management steps. The correct assessment of severity with CURB65 scoring, proper supportive measures and appropriate antibiotics are key to effective treatment of CAP.
[download-attachments container="div" style="list" dipslay_icon="1" display_count="1" display__size="0"]

References

1. Woodhead MA, Macfarlane JT, McCracken JS, et al. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987; i: 671–674.
2. Woodhead M, Welch CA, Harrison DA, et al. Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database. Crit Care 2006; 10 Suppl 2: S1.
3. BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax 2001; 56 Suppl 4: IV1–64.
4. Morgan M. Staphylococcus aureus, Panton-Valentine leukocidin, and necrotising pneumonia. Br Med J 2005; 331(7520): 793–794.
5. Riedel S, Beekmann SE, Heilmann KP, et al. Antimicrobial use in Europe and antimicrobial resistance in Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis 2007; 26(7): 485–490.
6. Torres A, Carlet J. Ventilator-associated pneumonia. European Task Force on ventilator-associated pneumonia. Eur Respir J 2001; 17(5): 1034–1045.
7. Lim WS, Macfarlane JT. A prospective comparison of nursing home acquired pneumonia with community acquired pneumonia. Eur Respir J 2001; 18(2): 362–368.
8. Christ-Crain M, Muller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J 2007; 30(3): 556–573.
9. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58(5): 377–382.
10. Subbe CP, Kruger M, Rutherford P, et al. Validation of a modified Early Warning Score in medical admissions. QJM 2001; 94(10): 521–526.
11. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243–250.
12. Barlow G, Nathwani D, Davey P. The CURB65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia. Thorax 2007; 62(3): 253–259.
13. Aujesky D, Auble TE, Yealy DM, et al. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. Am J Med 2005; 118(4): 384–392.
14. Confalonieri M, Potena A, Carbone G, et al. Acute respiratory failure in patients with severe community-acquired pneumonia. A prospective randomized evaluation of noninvasive ventilation. Am J Respir Crit Care Med 1999; 160(5 Pt 1): 1585–1591.
15. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32(3): 858–873.
16. Spencer RC. The role of antimicrobial agents in the aetiology of Clostridium difficile-associated disease. J Antimicrob Chemother 1998; 41 Suppl C: 21–27.
17. Dwyer R, Ortqvist A, Aufwerber E, et al. Addition of a macrolide to a sslactam in bacteremic pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis 2006; 25(8): 518–521.
18. Delaney JA, Dial S, Barkun A, et al. Antimicrobial drugs and communityacquired Clostridium difficile-associated disease, UK. Emerg Infect Dis 2007; 13(5): 761–763.
19. el MR, de Borgie CA, van den BP, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderatesevere community acquired pneumonia: randomised, double blind study. Br Med J 2006; 332(7554): 1355.
20. Halm EA, Fine MJ, Kapoor WN, et al. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med 2002; 162(11): 1278–1284.